Cadrenal Therapeutics (CVKD) Form 144 Discloses Founder Sale and Recent Dispositions

Rhea-AI Filing Summary

Form 144 notice for proposed sale of securities (Rule 144) filed for common stock to be sold on 09/24/2025 on NASDAQ. The notice lists 2,581 shares to be sold with an aggregate market value of $36,108 against 2,046,854 shares outstanding. The shares were acquired as Founders Shares on 01/25/2022. Recent sales by the same person are disclosed: 3,836 shares sold on 08/27/2025 for $53,455.56 and 1,193 shares sold on 08/28/2025 for $16,540.64. The filing includes a seller representation about absence of undisclosed material adverse information. Several issuer and filer identification fields in the form are blank or not provided in the supplied content.

Positive

• Disclosure of proposed sale amount and timing (2,581 shares planned for 09/24/2025)
• Provides acquisition history showing shares were acquired as founders shares on 01/25/2022
• Shows recent sales activity with dates and gross proceeds for aggregation under Rule 144

Negative

• Issuer name and filer identification fields are missing in the supplied content, limiting verification
• Submission contact information and filer CIK/CCC are not provided in the excerpt
• Remarks, signature, and exact dates for notice fields are not shown in the supplied text

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 notice showing planned sale and recent sales; key identifiers are missing from supplied text.

The filing documents a proposed sale of 2,581 common shares on NASDAQ with an indicated market value of $36,108 and confirms acquisition as founders shares on 01/25/2022. It also discloses two recent open-market sales totaling 5,029 shares and gross proceeds of $69,996.20, which is important for aggregation under Rule 144. However, critical issuer and filer identification fields are absent in the provided content, limiting confirmatory compliance checks such as CIK matching, exact issuer name, and submission contact details. From a compliance perspective the notice appears to follow the Rule 144 structure but the missing identifiers should be obtained to complete due diligence.

Corporate Governance Specialist

TL;DR: Disclosure of founders shares sale and recent disposals is material for insiders; missing issuer/filer details reduce transparency.

The form indicates a founder selling common stock originally acquired on 01/25/2022 and shows recent dispositions on 08/27/2025 and 08/28/2025 totaling 5,029 shares with combined gross proceeds of $69,996.20. This pattern could be relevant to shareholder dilution analysis and insider activity monitoring. The representation regarding no undisclosed material adverse information is standard. Because the supplied content omits the issuer name and filer CIK/contacts, investors and governance reviewers cannot fully reconcile the transaction to company records solely from this excerpt.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082	2581	36108	2046854	09/24/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/25/2022	Founders Shares	Issuer			2581	01/25/2022	N A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Quang Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/27/2025	3836	53455.56
Quang Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/28/2025	1193	16540.64

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does this Form 144 filing for CVKD report?

The filing reports a proposed sale of 2,581 common shares on 09/24/2025 on NASDAQ with an aggregate market value of $36,108.

When and how were the shares to be sold acquired?

The shares were acquired as Founders Shares on 01/25/2022 and the filing lists the nature of acquisition as founders shares.

Does the filing disclose recent sales by the same person?

Yes. It shows 3,836 shares sold on 08/27/2025 for $53,455.56 and 1,193 shares sold on 08/28/2025 for $16,540.64.

Is the issuer name or filer CIK included in the provided content?

No. The supplied excerpt does not include a clear issuer name, filer CIK, or submission contact details.

What does the filer represent by signing this Form 144?

The filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.